Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations

Anixa Biosciences, Inc. (ANIX)

4.94   0.05 (1.02%) 11-25 13:00
Open: 4.97 Pre. Close: 4.89
High: 4.98 Low: 4.82
Volume: 10,867 Market Cap: 151(M)

Technical analysis

as of: 2022-11-25 1:55:08 PM
Overall:       
Stoxline posted a BUY today, same as yesterday. Upward movement continues.
Target: Six months: 6.3     One year: 6.93
Support: Support1: 4.51    Support2: 3.76
Resistance: Resistance1: 5.39    Resistance2: 5.94
Pivot: 4.99
Moving Average: MA(5): 4.84     MA(20): 5.12
MA(100): 4.47     MA(250): 3.62
MACD: MACD(12,26): -0.1     Signal(9): -0.1
Stochastic oscillator: %K(14,3): 25.3     %D(3): 19.6
RSI: RSI(14): 48.1
52-week: High: 6.25  Low: 2.29
Average Vol(K): 3-Month: 96 (K)  10-Days: 48 (K)

Price, moving averages and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ ANIX ] has closed above bottom band by 43.9%. Bollinger Bands are 16.3% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 4.95 - 4.97 4.97 - 5
Low: 4.55 - 4.58 4.58 - 4.62
Close: 4.84 - 4.89 4.89 - 4.94

Company Description

Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell technology, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer; and the discovery and development of anti-viral drug candidates for the treatment of COVID-19 focused on inhibiting certain protein functions of the virus. Its vaccine programs comprise the development of a vaccine against triple negative breast cancer; and a preventative vaccine against ovarian cancer. The company is also developing immuno-therapy drugs against cancer. It has a collaboration agreement with MolGenie GmbH to discover and develop anti-viral drug candidates against COVID-19. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.

Headline News

Tue, 08 Nov 2022
2022-11-08 | NDAQ:ANIX | Press Release | Anixa Biosciences Inc. - Stockhouse

Mon, 31 Oct 2022
2022-10-31 | NDAQ:ANIX | Press Release | Anixa Biosciences Inc. - Stockhouse

Thu, 27 Oct 2022
THE ANIX Drops 90s Inspired Alt-Rock Grunge Single “See Nothing” - OUTBURN ONLINE - Outburn

Mon, 26 Sep 2022
We're Interested To See How Anixa Biosciences (NASDAQ:ANIX) Uses Its Cash Hoard To Grow - Simply Wall St

Mon, 15 Aug 2022
Anixa Biosciences Announces Treatment of First Patient in its Ovarian Cancer CAR-T Clinical Trial - PR Newswire

Tue, 21 Jun 2022
Anixa Biosciences Announces Publication of Peer-Reviewed Journal Article in Clinical and Experimental Vaccine Research Highlighting Ovarian Cancer Vaccine Technology - PR Newswire

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Neutral
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Neutral
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. -1 (M)
Shares Float 0 (M)
% Held by Insiders 3.066e+007 (%)
% Held by Institutions 2.929e+007 (%)
Shares Short 0 (K)
Shares Short P.Month 0 (K)

Stock Financials

EPS 127500
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) -0.52
Profit Margin (%) 0
Operating Margin (%) 2
Return on Assets (ttm) 868
Return on Equity (ttm) 538.4
Qtrly Rev. Growth -42.9
Gross Profit (p.s.) -0.01
Sales Per Share -0.01
EBITDA (p.s.) 0
Qtrly Earnings Growth 0
Operating Cash Flow 0 (M)
Levered Free Cash Flow 0 (M)

Stock Valuations

PE Ratio 0
PEG Ratio 0
Price to Book value -9.5
Price to Sales -82812.6
Price to Cash Flow 0

Stock Dividends

Dividend 642600
Forward Dividend 525350
Dividend Yield 13008100%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
android_stock_chart
StockChart iOS
stoxline_lite
StoxlineLite iOS
stoxline_pro
StoxlineLite iOS
Option_Calculator
OptionCalc iOS
android_stock_chart
StockChart Android
stoxline_lite
StoxlineLite Android
stoxline_pro
StoxlinePro Android
Option_Calculator
OptionCalc Android
(c) 2006-2022 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.